Recent progress in gene therapy for Parkinson's disease.

Area of Science:

• Neuroscience
• Genetics
• Neurology

Background:

• Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by the loss of dopaminergic neurons.
• Current treatments like L-dopa alleviate motor symptoms but cause adverse side effects with long-term use, including motor fluctuations and dyskinesia.

Purpose of the Study:

• To review preclinical and clinical gene therapy trials for Parkinson's disease.
• To evaluate the efficacy and safety of novel gene therapy approaches as alternatives to conventional treatments.

Main Methods:

• Review of clinical gene therapy trials for PD, including recombinant adeno-associated virus (AAV2) and equine infectious anemia virus (EIAV) based lentiviral systems.
• Assessment of gene therapies encoding aromatic L-amino acid decarboxylase (AADC), glutamic acid decarboxylase (GAD), Neurturin, tyrosine hydroxylase (TH), and GTP cyclohydrolase I (GCH).
• Analysis of data from phase I, I/II, and double-blind placebo-controlled phase II studies.

Main Results:

• Gene therapies involving GAD and Neurturin showed significant motor function improvements in phase II studies.
• AAV2 and EIAV-based lentiviral systems demonstrated significant effects in earlier phase studies (I/II).
• No adverse side effects related to surgical procedures were reported in the evaluated trials.

Conclusions:

• Gene therapy represents a promising curative treatment strategy for Parkinson's disease.
• Ongoing clinical trials indicate the potential of gene therapy to overcome limitations of current L-dopa treatments.
• Further investigation into these gene therapy approaches is encouraged for patients suffering from PD.